AstraZeneca has been developing cancer medicines for more than 40 years. Many of these have increased survival rates for patients in the UK and around the world. Leveraging its strength in oncology, AstraZeneca has established haematology as one of four key oncology disease areas of focus. Even as R&D continues to push boundaries in how we understand and fight cancer, there is still more to do.
GB-23722 December 2020